progressive MS

Abata Therapeutics has received an investment from Bristol Myers Squibb to support the development of its experimental regulatory T-cell (Treg) therapies for severe autoimmune and inflammatory diseases, including progressive multiple sclerosis (MS). The new equity investment from the global biopharmaceutical company follows last week’s green light from…

TG Therapeutics plans to soon launch a Phase 1 clinical trial to investigate the CAR T-cell therapy azercabtagene zapreleucel, or azer-cel, in people with progressive forms of multiple sclerosis (MS). The announcement comes after the U.S. Food and Drug Administration (FDA) cleared TG’s…

Abata Therapeutics is expected to launch a Phase 1 clinical trial by the end of the year to test ABA-101, its experimental therapy for progressive multiple sclerosis (MS), after getting a green light from the U.S. Food and Drug Administration (FDA). The FDA approved Abata’s investigational new drug…

Kyverna Therapeutics‘ cell-based therapy KYV-101 had an acceptable safety profile and promising treatment effects when given to two people with hard-to-treat progressive multiple sclerosis (MS), according to a case study. “We are very pleased about offering this potentially paradigm-shifting treatment opportunity to patients that have exhausted other medical…

Vitamin D supplements were associated with less severe disease in a rat model of progressive multiple sclerosis (MS), but male rats tended to experience greater benefits than did females, a study into disease-related sex differences reports. This higher overall benefit may be due to nerve cells in males being…

Repeated treatment with the mesenchymal stem cell therapy NG-01 led to gains in mobility and cognition, along with patient-reported quality of life, for most people with progressive multiple sclerosis (MS) in an extension study. Markers of nerve damage were also reduced, indicating significant nerve-protecting effects. Dimitrios Karussis, MD,…

Treatment with Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium (IMU-838) lowered the levels of a nerve damage marker in people with all subtypes of progressive multiple sclerosis (MS), including those without recent inflammatory activity. That’s according to an interim analysis of data from a Phase 2 study,…

Treatment options for progressive types of multiple sclerosis (MS) have expanded dramatically over the past decade, and several promising experimental therapies are in late stages of clinical development, a new review paper highlights. The study, “Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and…

The U.S. Food and Drug Administration (FDA) has cleared a Phase 2 clinical trial to test Kyverna Therapeutics‘ cell-based therapy candidate KYV-101 in people with treatment-resistant progressive multiple sclerosis (MS). Called KYSA-7 (NCT06138132), the open-label trial will enroll an estimated 12 patients with either primary progressive…

MediciNova announced the approval of a European patent covering the use of ibudilast (MN-166) in combination with interferon-beta medications to treat progressive forms of multiple sclerosis (MS) — primary progressive MS (PPMS) and secondary progressive MS (SPMS) — in patients previously using an interferon-beta.

A new clinical trial in Australia, called PLATYPUS, will simultaneously test two medications that have already been approved for other conditions in people with progressive forms of multiple sclerosis (MS). The study, expected to launch in January, will use an adaptive design, meaning data will be analyzed as…

ChariotMS, the world’s first clinical trial to test whether Mavenclad (cladribine) can slow the worsening of upper limb function in people with progressive multiple sclerosis (MS), has now enrolled 100 participants. The announcement means the Phase 2 trial (NCT04695080) has reached 50% of its target recruitment goal.

Immunic Therapeutics has been notified of the intent to grant a U.S. patent covering the use vidofludimus calcium (IMU-838) in treating relapsing forms of multiple sclerosis (MS) at a daily dose of about 10 to 45 mg. That range covers the two IMU-838 doses shown to be…

Vidofludimus calcium (IMU-838), an investigational oral therapy being developed by Immunic Therapeutics for all types of multiple sclerosis (MS), has demonstrated neuroprotective effects in people with progressive forms of the disease, interim clinical trial data show. The experimental therapy was associated with reductions in neurofilament light chain (NfL)…

Two non-pharmacological rehabilitation approaches — one using a computer program designed to improve working memory and the other involving standardized cognitive-behavioral group sessions — both improved the cognitive function of people with progressive forms of multiple sclerosis (MS), a new study reported. While varying medications often are used as…

Vitamin D reduced the signs of inflammation and nerve damage in a rat model of progressive multiple sclerosis (MS), a study shows. Low levels of the vitamin have been extensively linked with a higher risk of developing relapsing forms of the disease, but studies of vitamin D supplementation in…

Altered blood levels of certain fat molecules implicated in inflammatory responses seem to correlate with disability status and markers of nerve damage in people with multiple sclerosis (MS), particularly in those with progressive forms of the disorder, a study reported. Findings highlight the potential role of these fat, or…

It’s been three decades since the first treatment for multiple sclerosis (MS) was approved. In that time, the field has made substantial advances — including the approval of over two dozen medications — but there’s still a long way to go to improve care for progressive forms of…

The National Multiple Sclerosis Society has awarded Clene Nanomedicine a grant to advance its treatment candidate CNM-Au8 for people with nonactive, progressive forms of multiple sclerosis (MS). The funding comes from the MS Society’s Fast Forward Program, which supports commercial organizations developing promising new MS therapies,…

To mark World MS Day, which takes place annually on May 30, the International Progressive MS Alliance is introducing a research program to help drive early innovations in care programs for those with progressive forms of multiple sclerosis (MS). Specifically, the program seeks to identify solutions to…

Supplements with tauroursodeoxycholic acid (TUDCA) were generally well tolerated among people with progressive forms of multiple sclerosis (MS), according to findings from a small clinical trial. Results also showed that patients given TUDCA supplements had lower levels of certain inflammatory immune cells than those given a placebo, but no…

Use of the cell therapy MSC-NP failed to show a significant effect on overall disability scores among people with progressive forms of multiple sclerosis (MS), according to data from a Phase 2 clinical trial. Results, however, indicated that MSC-NP improved walking ability for people with more advanced disease —…

The world’s first mega-trial is recruiting people in the U.K. with progressive forms of multiple sclerosis (MS) to investigate the effectiveness of several approved therapies — at the same time. Named Octopus for its various arms, the study, which is expected to enroll at least 1,200 participants over…

Treatment with the experimental oral therapy ibudilast (MN-166) does not significantly improve quality-of-life measures compared with a placebo among people with progressive forms of multiple sclerosis (MS), according to new data from a Phase 2 clinical trial. Analyses from the trial suggest that a marker of nerve damage…

Changes in mitochondria — cells’ energy production centers — are evident in early disease stages in a mouse model of progressive multiple sclerosis (MS), but were not found in a model of relapsing-remitting MS (RRMS), according to researchers. These changes, seen before symptoms of the disease started, were…

The other day, my middle child opened the door while I was in the bathroom. If you have children, a surprise visit in what should be a sanctuary isn’t unusual, but in this case, what he said was. He observed me aboard my toilet and shower chair, which progressive…

Abata Therapeutics has chosen its first treatment candidate for development: the T-cell therapy ABA-101 for certain forms of progressive multiple sclerosis (MS). The therapy is now in early studies that aim to support an investigational new drug application or IND — a formal request to U.S. regulatory authorities…

You get used to … Hold on there, matey boy. Be honest and write “I.” This column has a reputation for brutal honesty (I’m sure someone has referred to it that way over the past five years), so don’t get all coy now that you’re not the center of medical…

The investigational immunotherapy ATA188 continues to ease disability and prevent brain tissue shrinkage in people with progressive forms of multiple sclerosis, according to the data, now reaching up to four years, on patients in an ongoing clinical trial. People who achieved confirmed disability improvement also showed potential signs of remyelination, or…

A new machine learning tool could help make clinical trials for progressive forms of multiple sclerosis (MS) more efficient and effective, a study suggests. Its scientists propose that the tool, when used in initial patient studies, works to more rapidly move a potential progressive MS treatment into pivotal Phase…